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Abstract
Refractive error (RE) is a complex, multifactorial disorder characterized by a mismatch between the optical power of the eye
and its axial length that causes object images to be focused off the retina. The two major subtypes of RE are myopia
(nearsightedness) and hyperopia (farsightedness), which represent opposite ends of the distribution of the quantitative
measure of spherical refraction. We performed a fixed effects meta-analysis of genome-wide association results of myopia
and hyperopia from 9 studies of European-derived populations: AREDS, KORA, FES, OGP-Talana, MESA, RSI, RSII, RSIII and
ERF. One genome-wide significant region was observed for myopia, corresponding to a previously identified myopia locus
on 8q12 (p = 1.2561028), which has been reported by Kiefer et al. as significantly associated with myopia age at onset and
Verhoeven et al. as significantly associated to mean spherical-equivalent (MSE) refractive error. We observed two genome-
wide significant associations with hyperopia. These regions overlapped with loci on 15q14 (minimum p value = 9.11610211)
and 8q12 (minimum p value 1.82610211) previously reported for MSE and myopia age at onset. We also used an
intermarker linkage- disequilibrium-based method for calculating the effective number of tests in targeted regional
replication analyses. We analyzed myopia (which represents the closest phenotype in our data to the one used by Kiefer
et al.) and showed replication of 10 additional loci associated with myopia previously reported by Kiefer et al. This is the first
replication of these loci using myopia as the trait under analysis. ‘‘Replication-level’’ association was also seen between
hyperopia and 12 of Kiefer et al.’s published loci. For the loci that show evidence of association to both myopia and
hyperopia, the estimated effect of the risk alleles were in opposite directions for the two traits. This suggests that these loci
are important contributors to variation of refractive error across the distribution.
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Introduction
Refractive errors (RE) are etiologically complex, multifactorial
disorders characterized by a mismatch between the optical focal
length of the eye and its axial length. This optical mismatch causes
images to be focused away from the retina. The two major
subtypes of spherical RE are myopia (nearsightedness) and
hyperopia (farsightedness). Clinically significant myopia affects at
least 25% of individuals over age 40 in the United States and
western Europe, while hyperopia affects about 10% of individuals
in this same age group [1]. Recent reports show that the
prevalence of myopia has increased significantly in the United
States over the last 3 decades; myopia of 2 (D) diopters or more
was estimated to afflict 41.6% of Americans aged 12 to 54 years in
1999–2004, compared to only 25% in 1971–1972 [2]. The
myopia epidemic is most acute in East Asia, where prevalence
estimates of myopia (of at least 0.5 D) routinely surpass 70%
among late teenagers and young adults [3,4,5]. A recent study of
19 year-old male military conscripts from Seoul, Korea, found that
a staggering 96.5% were myopic [6].
The causes of RE are complex and are a combination of
environmental and genetic factors [7]. Twin studies have reported
a heritability greater than 0.50 for RE [8]. Several studies have
calculated the heritability to be as high as 0.98 for myopia and
0.75 for hyperopia [9,10,11,12]. The search for environmental
factors influencing RE have mostly focused on myopia. These
include near work and time spent outdoors during childhood and
teenage years [13,14,15,16].
Genome-wide association studies have become an essential tool
in the study of traits such as RE, and to date there have been 67
published loci for refraction phenotypes [17]. In particular, Kiefer
et al. [18] performed a genome-wide association study of myopia
using self-reported age at onset in 45,771 participants and found
22 significant genome-wide associations. Verhoeven et al. [19]
performed a genome wide association of the quantitative trait
mean spherical equivalent (MSE) and found 24 significant
genome-wide associations (2 of which were replications of
previously published loci). [19]. Thirteen loci were genome-wide
significant in both the Kiefer et al. and Verhoeven et al. studies
[20].
Here we present the results of a genome-wide association meta-
analysis of 2 dichotomous RE traits, myopia and hyperopia
(adjusted for age, sex and years of education), in 9 populations: the
Age-Related Eye Disease Study (AREDS), the Cooperative Health
Research in the Region of Augsburg (KORA) the Framingham
Eye Study (FES), Ogliastra Genetic Park-Talana (OGP-Talana)
Study, the Multi-ethnic Study of Atherosclerosis (MESA), the
Rotterdam Eye Studies I, II and III (RSI, RSII, RSIII) and the
Erasmus Rucphen Family Study (ERF). These are termed the
discovery meta-analyses of myopia and hyperopia hereafter. Eight
of the discovery samples were previously included in the meta-
analysis of refractive error by Verhoeven et al. [19]. One sample,
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the MESA study, was not included in either Kiefer et al. [18]or
Verhoeven et al.’s [19,21]studies. We attempted replication of
significant and suggestive associations from the discovery meta-
analyses through meta-analysis of association studies using these
same trait definitions to these selected regions in 8 additional
studies: the 1958 British Birth Cohort, the Blue Mountains Eye
Study (BMES), the CROATIA-Vis Island Study, the CROATIA-
Korcula Study, the Diabetes Control and Complications Trial
(DCCT), the Orkney Complex Disease Study (ORCADES), the
TwinsUK Study, and the Wisconsin Epidemiologic Study of
Diabetic Retinopathy (WESDR). All of these studies were
previously included in the meta-analysis of refractive error by
Verhoeven et al. [19]. Finally, we examined the results of our
discovery meta-analyses of myopia and hyperopia in the regions
found to be associated with myopia age at onset by Kiefer et al.
[18]. In genetic association studies, the term replication is
generally used to mean detection of statistical association of the
same trait to the same associated genetic locus in an independent
set of data. Here, we also use the term replication when discussing
the results of our myopia trait (adjusted for age at examination, sex
and years of education) since it is expected to be quite similar to
the age at onset of myopia trait used by Kiefer et al. [18] in their
study. We show independent replication of 11 of Kiefer et al.’s loci
for myopia age at onset [18], and while our myopia trait is not
exactly the same as that of Kiefer et al. [18], it is the closest
phenotype available in our data. We also examined these same
regions for association to hyperopia. The association to hyperopia
would not constitute a ‘‘replication’’ of Kiefer et al.’s myopia
findings, but association with this related trait may help to clarify
the complex genetic underpinnings of refractive error.
Materials and Methods
Populations
The nine GWASs meta-analyzed in the discovery GWAS
portion of this study included subjects aged 35–84 years from the
Cooperative Health Research in the Region of Augsburg Study
(KORA F3, Southern Germany), subjects aged 55–80 from the
Age-related Eye Study (AREDS), unrelated subjects aged 28–84
from the Framingham Eye Study (FES), subjects aged 46-86 from
the Multi-Ethnic Study of Atherosclerosis (MESA) study, and
subjects aged 18–88 from the Ogliastra Genetic Park-Talana
(OGP-Talana) study in Sardinia, subjects aged 55 and older from
the Rotterdam Eye Study I, subjects aged 55 and older from the
Rotterdam Eye Study II, subjects aged 45 and older from the
Rotterdam Eye Study III, and subjects aged 18–86 from the ERF
study, resulting in a total sample size of 16,830 individuals for the
myopia analyses and 14,981 for the hyperopia analyses. All
individuals were of European ancestry. This study involved meta-
analysis of aggregate statistics from multiple studies. Approval was
obtained by the local ethics committees for all studies, all studies
were conducted according to the principles expressed in the
Declaration of Helsinki and informed consent was obtained from
the study participants at all study sites.
Study design
GWAS analyses of genotype data imputed to HapMap-II were
performed for the traits myopia and hyperopia (adjusted for age at
examination, sex and years of education) in 9 studies: the Age-
Related Eye Disease Study (AREDS), the ‘‘Kooperative Gesund-
heitsforschung in der Region Augsburg’’ (KORA, ‘‘Cooperative
Health Research in the Region of Augsburg’’), the Framingham
Eye Study (FES), the Ogliastra Genetic Park – Talana (OGP-
Talana) study, the Multiethnic Study of Atherosclerosis (MESA)
and the Rotterdam Eye Studies RSI, RSII, RSIII and the Erasmus
Rucphen Family Study (ERF). The results from these analyses
were then combined into a discovery meta-analysis GWAS of each
trait. Fixed effects meta-analyses were performed with METAL
[22] using p values and the effective sample size for each
population. METAL calculates a genomic control value [23] for
each population and then adjusts each population’s results using
the corresponding l value. The discovery meta-analysis genome-
wide significance threshold was taken to be 561028.
In an attempt to replicate our discovery meta-analysis results
and to increase the power of the analyses using our discovery
dataset, we obtained association results from 8 other studies, the
Blue Mountains Eye Study (BMES), CROATIA-Split, CROA-
TIA-Vis Island, CROATIA-Korcula studies, the Diabetes Control
and Complications Trial (DCCT), and the Orkney Complex
Disease Study (ORCADES) (Supplemental Methods), just for 30
genomic regions that contained SNPs with association p-values less
than 161025 to either myopia (11 regions) or hyperopia (14
regions) or both (5 regions) in our discovery meta-analysis (the
previously well-replicated association region on chromosome
15q14 was excluded). These studies all performed association of
SNPs in these regions with myopia and hyperopia (adjusted for age
at examination, sex, years of education when available and up to
three principal components when there was significant evidence of
population stratification in the data). A replication meta-analysis
was performed using the same methods as above on association
results in the novel genome-wide significant region for the
hyperopia trait in these 8 additional datasets. An additional
meta-analysis was then performed in these 30 regions combining
results from the discovery datasets and these 8 additional studies.
All 8 of these additional datasets were part of the Verhoeven et al.
study of mean spherical equivalent. This additional analysis and
these datasets are described in Materials S1–S3.
Quality control of discovery datasets
AREDS and KORA. Quality control measures are described
elsewhere [24] but in brief: Individuals with chromosome
abnormalities and sex discrepancies were removed. Cryptic
relatedness was estimated by calculating pairwise identical by
descent (IBD) coefficients. For each pair with a kinship coefficient
of 0.125 or greater, one member of the pair was dropped based on
genotyping rate and trait phenotype, preferring to retain the
person with higher genotyping rates and more extreme pheno-
types. Population stratification was assessed using principal
components. Batch effects and patterns of missingness were
eliminated by testing each batch against the others using Fisher’s
Exact test. As AREDS was a multi-center study, we also tested for
differences between collection sites. Samples were dropped for
poor performance on the array or a genotyping rate of ,98%.
SNPs were also removed from a population if its call rate was
below 99%, its minor allele frequency was below 0.01, or if its
distribution departed significantly from Hardy-Weinberg expec-
tations (p,161024) in a single population. We additionally
dropped SNPs in both populations where HWE p ,161024 in
1 population and HWE p ,161023 in the other. SNPs were also
excluded if they showed more than one genotype inconsistency
between HapMap control samples and the consensus genotype in
the HapMap database or investigator-provided duplicate samples.
Framingham Eye Study. Quality control measures are
described elsewhere [24] but in brief: Samples were chosen based
on pedigree information and genotyping quality. Samples with a
genotypic call rate below 95% were not chosen for analysis. The
mean call rate for analyzed samples was 99.2% (SD=0.4%). The
final marker list contained 436,494 high-quality SNPs with a
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minor-allele frequency.=0.01, a Mendelian error rate below 2%
across all pedigrees, a genotype call rate above 95%, and whose
distribution was consistent with Hardy-Weinberg expectations (P.
161024).
MESA. For the MESA dataset, SNPs with MAF less than 0.02
or HWE p value less than 0.001 were removed from the analysis.
Genotyping was performed using the Affymetrix Genome-Wide
Human SNP Array 6.0. IMPUTE version 2.1.0 was used to
perform imputation for the MESA Caucasian participants
(chromosomes 1–22) using HapMap Phase I and II - CEU as
the reference panel (release #24 - NCBI Build 36 (dbSNP b126)).
SNPs with genotype call rate less than 0.95, MAF less than 0.02,
HWE p value less than 0.001, or oevar less than 0.3 were removed
from the analysis. Association tests were performed by SNPTEST
v2 (Marchini et al., 2007).
OGP-Talana. Quality control of the SNP data was per-
formed using the GenABEL software package in R. Samples with
overall SNP call rate ,93%, with minor allele frequency ,0.01,
with Hardy-Weinberg P value.1026, showing excess heterozy-
gosity, or being classified as outliers by allelic identity-by-state
(IBS) clustering analysis, were excluded.
Rotterdam eye studies I,II and III
Subjects with cataracts and history of cataract or refractive
surgery were excluded from the study. DNA was extracted from
blood leucocytes according to standard procedures. Genotyping of
SNPs was performed using the Illumina Infinium II Human-
Hap550 chip v3.0 array (RS-I); the HumanHap550 Duo Arrays
and the Illumina Human610-Quad Arrays (RS-II), and the
Illumina Human 610 Quad Arrays (RS-III). Samples with low
call rate (,97.5%), with excess autosomal heterozygosity (.0.336),
or with sex-mismatch were excluded, as were outliers identified by
the identity-by-state clustering analysis (outliers were defined as
being.3 s.d. from population mean or having identity-by-state
probabilities.97%). GWAS analyses were performed using
GRIMP.
Erasmus rucphen family study
Subjects with cataracts and history of cataract or refractive
surgery were excluded from the study. DNA was genotyped on
one of four different platforms (Illumina 6k, Illumina 318K,
Illumina 370K and Affymetrix 250K). Samples with low call rate
(,97.5%), with excess autosomal heterozygosity (.0.336), or with
sex-mismatch were excluded, as were outliers identified by the
identity-by-state clustering analysis (outliers were defined as
being.3 s.d. from population mean or having identity-by-state
probabilities.97%). GWAS analyses were performed using the
ProbABEL package from the ABEL set. A lambda correction was
performed to adjust for cryptic relationship.
Genotype imputation of data
To produce a consensus set of genotypes for imputing to the
HapMap-II, AREDS and KORA high quality SNPs were filtered
to those present on HapMap-II. Imputation to the HapMap-II
reference panel (CEU population release 22, NCBI build 36) was
performed in MACH [22,25] in 2 stages. Stage one was the model
parameter estimation stage which used a random sample of 300
individuals from each population, using the greedy option which
only uses the reference haplotypes (supplied here from the
HapMap) and 100 Markov Chain iterations. Stage two is the
actual imputation stage and uses the model parameters estimated
in stage one to speed up the imputation of the genotypes. After
imputation, the remaining high quality genotyped SNPs were
merged back in with the SNPs from the imputation procedure for
the AREDS and KORA data. For the FES data, genotype
imputation to the HapMap-II reference panel (CEU population
release 22, NCBI build 36) was carried out in a two-step process
using the Markov Chain Haplotyping (MACH version 1.0.16.a)
software. First, crossover and error-rate maps were built using 400
unrelated individuals (200 male and 200 female) sampled from
FHS subjects. Second, genotype imputations of approximately 2.5
million autosomal HapMap-II SNPs were carried out on the entire
FHS dataset using parameters estimated from step 1. For MESA,
IMPUTE version 2.1.0 was used to perform imputation for the
Caucasian participants (chromosomes 1-22) using HapMap Phase
I and II - CEU as the reference panel (release #24 - NCBI Build
36 (dbSNP b126)). For OGP-Talana, using the phase II CEU
HapMap individuals (release 22, NCBI build 36) as reference
panel for imputation, genotypes were imputed for nearly 2.5
million SNPs using MACH. SNPs imputed with Rsq ,0.3 were
excluded. For RSI,II and III and ERF, a set of genotyped input
SNPs with call rate.98%, with minor allele frequency.0.01, and
with Hardy-Weinberg P value.1026 was used for imputation. We
used the Markov Chain Haplotyping (MACH) package version
1.0.15 software (Rotterdam, The Netherlands; imputed to plus
strand of NCBI build 36, HapMap release #22) for the analyses.
For each imputed SNP, a reliability of imputation was estimated as
the ratio of the empirically observed dosage variance to the
expected binomial dosage variance (O/E ratio).
Data analysis
Genetic association was estimated by fitting a logistic regression
model separately to the traits myopia and hyperopia. To create the
dichotomous traits, we calculated mean spherical equivalent
(MSE) as the average of spherical equivalent (SE) of refraction
between the two eyes, or the single SE value for persons with only
a single SE measurement. For myopia, cases were defined as MSE
,21D, controls.0D and individuals between 0D and 21D
coded as unknown. For hyperopia, cases were defined as MSE.+
1D, controls ,0D and individuals between 0D and +1D coded as
unknown. A general additive genetic model was used to code the
SNP effect (i.e. SNPs were coded according to the number of
minor alleles [0,1,2] for each person); covariates included age; sex;
and years of education. For AREDS, KORA and FES, this was
accomplished using the PLINK (version 1.07) statistical software
(http://pngu.mgh.harvard.edu/,purcell/plink) [26]. For AREDS
analyses, the first three principal components (eigenvectors) of the
EIGENSTRAT analysis were also included along with the
covariates listed above. For MESA, these association tests were
performed by SNPTEST v2.52. For OGP-Talana, all regression
models were run using the ProbABEL package from the ABEL set
of programs which adjusts jointly for cryptic relationship and
population stratification. For RSI, II and III and ERF, we used
genomic control [23] to obtain optimal and unbiased results and
Figure 1. Q-Q and Manhattan Plots for the myopia analysis of all cohorts. a) Q-Q plot for association between all SNPs analyzed and myopia
in the meta-analysis. Each dot represents an observed statistic (defined as -log10 P) versus the corresponding expected statistic. The red line
corresponds to the null distribution. b) Manhattan plot for association between all SNPs analyzed and myopia in the meta-analysis. Each dot
represents an observed statistic (defined as -log10 P). The darker gray line corresponds to the genome-wide significance threshold and the lighter
gray line represents the suggestive threshold.
doi:10.1371/journal.pone.0107110.g001
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applied the inverse variance method of each effect size estimated
for both autosomal SNPs that were genotyped and imputed in
both cohorts.
Association analyses were performed for both traits and a
genome-wide meta-analysis was performed on the 9 populations
and 8 replication data sets (Blue Mountains Eye Study, Croatia Vis
Island Study, Croatia Korcula Study, Diabetes Control and
Complications Trial, Orkney Complex Disease Study, UK Twins
Study, 1958 British Birth Cohort, Wisconsin Epidemiologic Study
of Diabetic Retinopathy). Details of the genome-wide analyses of
the individual discovery datasets and the replication analyses are
shown in the supplemental methods and results including QQ-
plots and Manhattan plots for each of the discovery cohorts in
Figures S1-S9. Figure S10 is a flowchart showing the workflow of
the entire study.
SNP selection for replication
Thirty genomic regions that contained SNPs with association p-
values less than 161025 to either myopia (11) or hyperopia (14) or
both (5) in our discovery meta-analysis (excluding the 15q14
region) were chosen for replication or further study in the 8
additional datasets. We analyzed all SNPs within a 500 kb window
centered on the most significant SNP in each region from the
discovery meta-analysis.
For the comparison of our discovery meta-analysis results with
the myopia age at onset loci from the Kiefer et al. [18] study, a list
of strongly associated variants that were genome-wide significant
(p#561028) or suggestive (p,161026) in Kiefer et al. [18] was
selected. We analyzed all SNPs within a 500 kb window centered
on these replication SNPs in our data.
Calculation of effective number of tests and replication
significance thresholds
It has become increasingly clear that only attempting to
replicate the exact SNPs found to be genome-wide significant in
a discovery GWAS can produce a failure to replicate due to
underlying differences in linkage disequilibrium (LD) and allele
frequencies [27,28], even in populations self-identified as having
the same ethnicity. Ioannidis et al. [29] have shown that restricting
replication efforts to only a few of the most significant SNPs from
an associated region leads to less robust information for those loci.
The resulting failure to replicate may be because those selected
SNP(s) are not necessarily more informative or closer to the causal
variant than other SNPs in the region. Several approaches to this
problem have been proposed, including incorporating linkage
information [30], pathway-based association [31] and other
methods which use multiple SNPs in the analysis
[32,33,34,35,36,37,38,39]. A linkage disequilibrium (LD) based
binning strategy, proposed by Christoferou [39] may prove to be
the most useful. However, the issues of handling SNPs which map
to more than one gene due to overlapping reading frames and the
correlations between genes and derivative gene scores still need to
be resolved. Until that problem has a solution, it may be more
powerful to study a dense panel of SNPs from each associated
region, and utilize imputation to the latest version of 1000
Genomes data to provide additional genotypes to harmonize
available SNPs across studies even when genotyped on different
platforms. Here we selected all SNPs that were within a specified
window of the original SNP and used the method of Ramos et al.
[40] to model the LD structure in one of the replication
populations to calculate the effective number of independent tests
being performed across all of our replication regions. Traditional
methods of correcting for multiple comparisons, such as the widely
used Bonferroni correction considering all SNPs tested, are
notoriously conservative because they do not take intermarker
correlation fully into account but treat all the tests as independent.
By using the effective number of independent tests in a Bonferroni
correction, Type I error is still controlled and power is improved.
Various approaches to calculating the effective number of
independent tests when using such a regional replication strategy
have been proposed since many of the SNPs in such a region are
in LD with each other and do not represent independent tests
[41,42,43,44,45], although many of these approaches are still
overly conservative. The Ramos et al. [40] approach properly
accounts for SNP interdependence, allows computation of the
effective number of independent tests for very large numbers of
highly correlated SNPs and is less computationally intensive than
permutation-based methods. We used the method of Ramos et al.
[40] to calculate the number of effective tests (Neff) in all the
replication regions and divided a by this effective number of tests
to calculate the significance threshold separately in the AREDS,
KORA and Framingham datasets. The Ramos method calculates
Neff by first estimating the KxK covariance matrix for the K SNPs
in the replication regions using the genotype data. Then the
covariance matrix is spectrally decomposed to calculate the
eigenvalues. The effective number of tests is then estimated using
the relationship
Neff~
XK
k~1
lk
 !2
=
XK
k~1
l2k
 !
in which lk is the kth eigenvalue of the K6K covariance matrix
for the K SNPs [46]. The Bonferroni-corrected significance
threshold is then calculated as a/Neff.
The markers in each region are very densely spaced, with high
levels of LD between markers in each block. The calculations from
the AREDS data gave the largest effective number of tests and
thus the most conservative Bonferroni-corrected significance
threshold; thus this was chosen as our significance threshold for
our replication studies. However, the Bonferroni-corrected
thresholds derived by applying this method to the KORA and
Framingham data were only slightly less conservative than the
threshold derived from the AREDS data.
Results
After all quality control measures and appropriate association
analyses, genome-wide association results from Caucasian partic-
ipants in the AREDS, KORA, FES, OGP-Talana, MESA, RSI,
RSII, RSIII and ERF studies were combined in a genome-wide
discovery meta-analysis totaling 16,830 individuals for myopia and
14,981 individuals for hyperopia. Table 1 describes the charac-
teristics of the populations after classifying participants into
myopia, hyperopia, control or unknown categories.
Figure 2. Q-Q and Manhattan Plots for the hyperopia analysis of all cohorts. a) Q-Q plot for association between all SNPs analyzed and
hyperopia in the meta-analysis. Each dot represents an observed statistic (defined as -log10 P) versus the corresponding expected statistic. The red
line corresponds to the null distribution. b) Manhattan plot for association between all SNPs analyzed and hyperopia in the meta-analysis. Each dot
represents an observed statistic (defined as -log10 P). The darker gray line corresponds to the genome-wide significance threshold and the lighter
gray line represents the suggestive threshold.
doi:10.1371/journal.pone.0107110.g002
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Testing for population stratification using EIGENSOFT and
principal components analysis found no evidence of population
stratification in KORA, but some evidence of substructure was
detected in the AREDS, FES and MESA studies. These were
adjusted for in the genome-wide association analyses by including
the first three principal components from the PCA as covariates in
our regression models. The OGP-Talana data were also adjusted
for cryptic relatedness using the ProbABEL R package. For ERF
and RS1–3, the population was assumed to be homogeneous and
outliers excluded. Genomic control [23] values (l) calculated by
METAL [47] for each population prior to meta-analysis for each
trait are given in Table 1. These values were used by METAL to
adjust each population’s results before including in the fixed effects
meta-analysis. The QQ plots of the meta-analysis p values
(Figure 1a and Figure 2a) showed some deviation from the null.
However, the genomic control method [23] was used to further
control for population stratification and inter-population differ-
ences in the final meta-analysis. The variance inflation factors
calculated by METAL [47] for the final meta-analysis across the
nine cohorts for myopia and hyperopia were 1.038 and 1.046
respectively. Lambda values ranging from approximately 0.95 to
1.1 are considered desirable.
Results of the genome-wide meta-analyses are shown in
Figure 1b and Figure 2b and results for each sample separately
are given in Figure S1 (AREDS), Figure S2 (KORA), Figure S3
(FES), Figure S4 (MESA), Figure S5 (OGPT), Figure S6 (RS-I),
Figure S7 (RS-II), Figure S8 (RS-III), Figure S9 (ERF). Eight
additional studies (1958 British Birth Cohort, BMES, CROATIA-
Vis, CROATIA-Korcula, DCCT, ORCADES, TwinsUK and
WESDR) were used for replication and baseline characteristics of
these studies can be found in Table S3. Results of further meta-
analyses of genomic regions that exhibited suggestive evidence of
association with myopia or hyperopia using regional results from
the 8 additional studies listed above are given in Tables S6 and S7.
Meta-analyses combining the replication region association results
from the 9 discovery datasets and the 8 replication datasets did not
result in genome-wide significant results, except for the 8q12 locus
(results not shown) that was already genome-wide significant in the
discovery dataset.
To determine if our discovery meta-analyses showed evidence of
association in any of 35 loci (Table S1) reported to exhibit
genome-wide significant or suggestive (p,161026) association
with myopia age at onset by Kiefer et al. [18], a total of 33,591
SNPs overlapping all associated loci were selected (Table S2).
These included the most significant discovery SNP plus all
available genotyped and imputed SNPs within 500kb of the most
significant discovery SNP (Table S2). Accounting for all the LD in
each region reduced the effective number of tests, Neff, to 475.71.
The replication significance threshold, calculated while taking into
account this LD structure in replication regions [40], was
a
Neff
~
0:05
475:71
~0:0001.
Myopia
Results of the discovery meta-analysis (Figure 1, Table S4)
shows one genome-wide significant marker corresponding to a
previously identified myopia age at onset [18] and refractive error
[19] locus on 8q12 (rs10113215, p = 1.2561028). We also
observed association to the well-replicated locus on 15q14 (near
GJD2) that was close to genome-wide significant (rs1370156,
p = 2.2961027). No attempt was made to replicate the chromo-
some 15q14 region since it has been well replicated. SNPs in the
8q12 replication region did not reach the replication threshold (for
rs10113215, replication p= 0.02; top replication p-value in the
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region was p= 0.0022 for rs6995115). For the discovery meta-
analysis suggestive regions, one of the selected SNPs achieved the
replication threshold for myopia (rs4326350 on 8p23,
p = 6.161025). However, it should be remembered that this
region did not exhibit genome-wide significant association in the
discovery meta-analysis (replication p-values in Table S6).
In addition to the 8q12 locus, 10 other myopia age at onset
regions from the Kiefer et al. study [18] showed significant
evidence of replication in our discovery meta-analysis (Table 2).
Eight of these loci have also been reported as associated with MSE
by Verhoeven et al. [19]. However, two of the regions we
replicated were not reported significantly associated with MSE by
Verhoeven et al. [19]. On chromosome 3p26, rs2587916 reached
the replication threshold in our discovery meta-analysis
(p = 2.7961025). This SNP is 256 bp away from the SNP reported
in this region by Kiefer et al. [18], rs1843303 (which had
p= 6.3261024 in our data, Table 2). These two SNPs exhibit
strong linkage disequilibrium with an R2 of 0.963 and a D9 of 1 in
our data. The most significant SNP at the second locus on
chromosome 6 is the same SNP as reported by Kiefer et al. [18],
rs7744813 (p= 6.0761026, Table 2).
Due to the high genomic control values for OGP-Talana and
ERF (Table 1), we examined QQ plots of only the common SNPs
(MAF.0.2) to see if this made an improvement, since all the
associated SNPs reported here have high MAFs. In OGP-Talana
this improved the QQ plots (Figure S9) but it made no difference
for ERF. Therefore, we dropped ERF from the analysis and re-
examined the results (Figure 3). For most loci this made minimal
difference to the p values. However, for 3 loci there was a
considerable difference. The genome-wide significant result for
myopia on chromosome 8 was no longer genome-wide significant
(p = 8.861027), although it still remained well below our
replication significance threshold. The loci on 2q37 and 3p26
were no longer below our replication threshold.
Hyperopia
Meta-analysis results showed two genome-wide significant
associations with hyperopia (Figure 2, Table S5). These regions
overlapped with loci on 15q14 (rs11073060, p = 9.11610211) and
8q12 (rs10089517,p = 1.82610211) previously reported for MSE
in Verhoeven et al. [19] and for myopia age at onset in Kiefer et
al. [18]. No attempt was made to replicate the 15q14 locus since it
has been well replicated for MSE. None of the SNPs selected to
attempt replication of the discovery meta-analysis genome-wide
significant association with hyperopia on chromosome 8q12
achieved the replication threshold (rs10089517, p= 0.08; top
replication p-value in the region was 0.014 at rs11778476) (Table
S7). In addition, for the discovery meta-analysis suggestive regions,
one SNP achieved the replication threshold for hyperopia
(rs12660628 on 6q21, p = 7.761025). However, it should be
remembered that this region did not exhibit genome-wide
significant association in the discovery meta-analysis (replication
p-values in Table S7).
In addition to the 15q14 and 8q12 loci, 10 other regions
(Table 3) that were genome-wide significant in the Kiefer et al.
[18] analysis of myopia age at onset exhibited p values for
association with hyperopia that met our ‘‘replication’’ threshold
for these regions. Given this is a different but related trait, this
finding is interesting. Five of these regions have been replicated
using myopia as the trait in our data here (three of which were also
found to be significantly associated with MSE by Verhoeven et al.
[19]). Verhoeven et al. [19] also found that 1 more of these 10
regions (Table 3) showed significant association with MSE. Of the
remaining 4 regions from Table 3 the most significant of these 4
SNPs was rs1371993 (p = 1.1361025), a SNP on chromosome 4,
35Kb from the SNP reported by Kiefer et al. [18] for myopia age
at onset (rs1031004, not available in our data).
Due to the high genomic control values for OGP-Talana and
ERF (Table 1), we examined QQ plots of only the common SNPs
(MAF.0.2) to see if this made an improvement, since all the SNPs
reported here have high MAFs. In OGP-Talana this improved the
QQ plots (Figure S9) but it made no difference for ERF.
Therefore, we dropped ERF from the analysis and re-examined
the results (Figure 4). For all loci this made minimal difference to
the p values and did not change the conclusions.
Discussion
We conducted a meta-analysis of 9 myopia and hyperopia
genome-wide association studies. We detected the known loci on
chromosomes 8q12 and 15q14. The locus on chromosome 8q12
has been reported associated with mean spherical equivalent in an
analysis which included many of the cohorts in this study [19], and
myopia age at onset in an independent study [18]. The locus on
chromosome 15q14 was discovered in some of the cohorts
included in this analysis [48] and has been well replicated in
studies of both MSE [21] and myopia age at onset [18]. These
findings were therefore expected. However, the signal for 15q14 is
only genome-wide significant in the hyperopia analysis here. In
addition, although the 8q12 locus was genome-wide significant in
the myopia analysis, it was more significant in the hyperopia
analysis. Nonetheless, the direction of effect of these SNPs is
exactly opposite in the myopia and hyperopia analyses –
suggesting that the causal mechanisms being tagged by these
SNPs are operating across the spectrum of refractive error.
We also examined the results of our discovery meta-analyses of
myopia (which were adjusted for age at examination and years of
education) to attempt targeted ‘‘replication’’ of 35 GWAS-
identified loci that have previously been reported by Kiefer et al.
to be associated with age at onset of myopia [18]. Since age at
onset was not available in all our study samples, it was not possible
to perform an exact replication of the Kiefer et al. [18] trait on
which they performed survival analysis of myopia age at onset.
Our analyses, where we included age at exam and years of
education, is the closest phenotype we had available. We also
examined evidence for association with hyperopia in these same
regions of the genome, since myopia and hyperopia represent
opposite ends of the distribution of refractive error. It is reasonable
that loci that affect the variability of MSE as a whole may
therefore affect risk of both myopia and hyperopia.
Our analysis provides evidence for replication of a number of
loci identified by Kiefer et al. [18]. Those which were replicated
using the myopia trait (Table 2) represent the closest phenotype
available from all of our samples to the one used in their analysis.
In particular, this study presents the first report of replication of 11
Figure 3. Q-Q and Manhattan Plots for the myopia analysis excluding the ERF cohort a) Q–Q plot for association between all SNPs
analyzed and myopia in the meta-analysis excluding the ERF cohort. Each dot represents an observed statistic (defined as -log10 P) versus
the corresponding expected statistic. The red line corresponds to the null distribution. b) Manhattan plot for association between all SNPs analyzed
and myopia in the meta-analysis excluding the ERF cohort. Each dot represents an observed statistic (defined as -log10 P). The darker gray line
corresponds to the genome-wide significance threshold and the lighter gray line represents the suggestive threshold.
doi:10.1371/journal.pone.0107110.g003
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regions associated with myopia. Of note, nine of these regions also
showed genome-wide significant evidence of association to MSE
by Verhoeven et al. [49]: chromosome 2 near PRSS56 (MIM:
609995), chromosome 4 near BMP3 (MIM:112263), chromosome
6 near LAMA2 (MIM:156225), chromosome 8 near ZMAT4
(40734662 bp), chromosome 8 near TOX (MIM:606863,
60178580 bp), chromosome 10 near BICC1 (MIM: 612717),
chromosome 13 near ZIC2(MIM:603073)/ZIC5, chromosome 15
near GJD2 (MIM:607058) and chromosome 16 near RBFOX1(-
MIM:605104). The candidate genes in these 9 regions have been
discussed by both Kiefer et al. [18] and Verhoeven et al. [19]. The
two remaining Kiefer et al. loci that were not reported as
significantly associated with MSE in Verhoeven et al. [19] were on
3p26.1 and 6q13. The SNP reported by Kiefer et al. [18] in the
3p26.1 region did not meet our replication threshold but another
SNP, only 256bp away and in strong linkage disequilibrium with
this SNP, did meet our threshold. Kiefer et al. [18] proposed the
nearby gene SETMAR (MIM:609834), a histone methylation and
DNA repair gene as a candidate to explain their observed
association with myopia. However, both the SNP detected in our
study and the SNP reported by Kiefer et al. [18] are intronic to
one transcript of SUMF1 (MIM:607939), which codes for an
enzyme that catalyzes the hydrolysis of sulfate esters. Mutations in
this gene are known to cause the lysosomal storage disorder
multiple sulfatase deficiency. This multisystem syndrome has been
reported to have ocular phenotypes, in the form of retinal
degeneration and nystagmus [50]. However, this signal on 3p26.1
was no longer a significant replication when the ERF study results
were removed from the analysis. While the Q-Q plot of the ERF
study results shows some deviation from expected, it does not
appear to exhibit overall inflation of the false positive rate for this
sample. Thus the replication of this 3p26 locus using all 9 studies
may be valid but additional evidence from a larger study will be
useful in determining the importance of this locus to risk of
myopia. In the 6q13 region, our study replicated the exact same
SNP that was reported to have the strongest association with
myopia age at onset in the Kiefer et al. [18] study and this result
did not change with the removal of the ERF study results from our
meta-analysis. This associated SNP is in an intron of the KCNQ5
gene (potassium voltage-gated channel, KQT-like subfamily,
member 5, MIM:607357), which is a member of the KCNQ
potassium channel gene family. KCNQ5 has been shown to be
differentially expressed in subregions of the brain and in skeletal
muscle [51]. Voltage-dependent potassium channels are important
regulators of the resting membrane potential and affect the
excitability of electrically active cells (MIM: 607357). KCNQ5 is
also expressed in the retinal pigment epithelium (RPE) and neural
retina. These potassium channels are believed to affect ion flow
across the RPE [52] and the function of cone and rod
photoreceptors [52,53].
Other regions that were found to be significantly associated with
myopia by Kiefer et al. [18] showed some evidence of association
with hyperopia but not with myopia in our data. The significance
levels of these associations reached our ‘‘replication’’ threshold.
This intriguing result suggests that these loci may not be myopia
specific. However, much larger sample sizes will be required to
further investigate this issue.
One of the Kiefer et al. [18] loci that did not replicate in the
analysis of myopia and was not previously reported as significantly
associated with MSE was a locus on 2q31.2. This locus showed
evidence of association with hyperopia in our data that reached
our ‘‘replication’’ threshold. Kiefer et al. suggested that this
association might be due to variants in the phosphodiesterase 11A
gene (PDE11A, MIM:604961), which as a known cell signaling
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molecule is a good candidate gene for development of refractive
errors, given the importance of neural signaling in the control of
eye growth. However, the signal in our hyperopia analysis
stretches across 3 genes: PDE11A; tetratricopeptide repeat
domain 30A (TTC30A) protein; and alkylglycerone phosphate
synthase (AGPS, MIM:603051). Mutations in AGPS are associ-
ated with rhizomelic chondrodysplasia punctata, type 3, a
multisystem developmental disorder in which patients frequently
develop cataracts [54].
For the locus on chromosome 4 that showed some evidence of
association with hyperopia in our data, Kiefer et al. [18] suggested
that ANTXR2 (MIM:106490), a gene involved in extracellular
matrix adhesion was the best candidate, but other good candidates
exist in this region such as BMP2 inducible kinase (BMP2K) and
annexin A3 (ANXA3, MIM:106490) a gene involved in regulation
of cell growth and signal transduction pathways. Two other bone
morphogenic proteins whose genes are located elsewhere in the
genome have been identified as candidate genes by Kiefer et al.
[18] and Verhoeven et al. [19] and have also been observed in
animal models of myopia [55,56]. The role of this group of genes
in growth regulation is well known [57].
Given that hyperopia and myopia are the extreme ends of the
refractive error distribution, it is tempting to assume that the same
risk factors must affect the risk of developing both traits equally.
However, it is not yet clear whether those environmental and
genetic factors which increase the risk of developing myopia
necessarily affect the risk of hyperopia. The results presented here
provide some tantalizing evidence that some genetic factors may
be important in both traits whereas others may be more important
in driving myopization than hyperopization or vice versa. It has
now been shown that 9 regions (2q37, 4q21, 6q22, 8p11, 8q12,
10q21, 13q32, 15q14, 16p13) show association to age at onset of
myopia [18], myopia adjusted for age at exam, sex and years of
education (results presented here) and mean spherical equivalent
[19]. However, we observed replication-level association with
myopia for an additional 2 loci (6q13 and 8p11) which were not
genome-wide significant for mean spherical equivalent [19] but
were genome-wide significant for myopia age at onset [18]. An
additional four regions that were genome-wide significant in the
Kiefer et al. analysis of age at onset of myopia [18] have only been
‘‘replicated’’ in our hyperopia analyses. These results indicate that
the genetic underpinnings of refractive errors are quite complex
and that analyses of both the qualitative and quantitative
phenotypes may add to our understanding of refractive error
causation. The study participants whose data were analyzed here
were not selected for extreme or ‘‘high’’ myopia (typically defined
as SE,-6D) and there were very few individuals with high myopia
in any of these datasets. Future studies to examine whether any of
the loci that show association to myopia, hyperopia and mean
spherical equivalent in the population-based studies also show
evidence of association to high myopia would be interesting and
should be pursued.
Some of the other loci that showed significant association with
myopia in the Kiefer et al. [18] study did not replicate in our
current study. Dichotomizing the trait from spherical equivalent to
myopia or hyperopia in each population did reduce sample size for
each population compared to the number of individuals with
measurements of spherical equivalent. This consequent reduction
in power was the reason we added additional populations to our
discovery meta-analysis compared to our refractive error meta-
analysis [24], to offset the lower sample size. This current study is
still, however, smaller than the Kiefer et al. [18] study we were
attempting to replicate and so some of the other loci may yet
replicate in a larger study.
In summary, we have provided evidence in favor of replication
of 11 loci involved in causation of myopia. Twelve loci that have
been shown to be associated with myopia age at onset [18] showed
‘‘replication-level’’ association with hyperopia here (7 of these loci
also showed replication-level association with the myopia trait; 5
loci only showed this level of association with hyperopia). Further
research is required to determine whether any of the candidate
genes identified near these associated SNPs are truly causing the
development of refractive errors, or whether the actual causal
variant is located in another nearby gene or other functional locus
in high LD with the SNPs associated with the trait. Evidence for
expression of many of these genes have indicated that they are
active in the eye [19] and investigation of the ENCODE data
suggests many loci have regulatory functions, which is consistent
with the current hypothesis of regulation of eye growth through a
visually-evoked signaling cascade. However, more research using
in vitro and in vivo models is necessary to elucidate the underlying
mechanisms of normal emmetropization and how it can be
disrupted to produce refractive errors.
Supporting Information
Figure S1 QQ and Genome-wide Manhattan plot of
genotyped and imputed SNPs for association with
myopia (A,C) and hyperopia (B,D) in AREDS.
(TIF)
Figure S2 QQ and Genome-wide Manhattan plot of
genotyped and imputed SNPs for association with
myopia (A,C) and hyperopia (B,D) for KORA.
(TIF)
Figure S3 QQ and Genome-wide Manhattan plot of
genotyped and imputed SNPs for association with
myopia (A,C) and hyperopia (B,D) for Framingham
Eye Study.
(TIF)
Figure S4 QQ and Genome-wide Manhattan plot of
genotyped and imputed SNPs associated with myopia
(A,C) and hyperopia (B,D) in MESA.
(TIF)
Figure S5 QQ and Genome-wide Manhattan plot of
genotyped and imputed SNPs for association with
myopia (A,C) and hyperopia (B,D) in OGP-Talana.
(TIF)
Figure S6 QQ and Genome-wide Manhattan plot of
genotyped and imputed SNPs for association with
myopia (A,C) and hyperopia (B,D) in ERF.
(TIF)
Figure 4. Q-Q and Manhattan Plots for the hyperopia analysis excluding the ERF cohort a) Q-Q plot for association between all
SNPs analyzed and hyperopia in the meta-analysis excluding the ERF cohort. Each dot represents an observed statistic (defined as -log10
P) versus the corresponding expected statistic. The red line corresponds to the null distribution. b) Manhattan plot for association between all SNPs
analyzed and hyperopia in the meta-analysis excluding the ERF cohort. Each dot represents an observed statistic (defined as -log10 P). The darker
gray line corresponds to the genome-wide significance threshold and the lighter gray line represents the suggestive threshold.
doi:10.1371/journal.pone.0107110.g004
Genome-Wide Meta-Analysis of Myopia and Hyperopia
PLOS ONE | www.plosone.org 16 September 2014 | Volume 9 | Issue 9 | e107110
Figure S7 QQ and Genome-wide Manhattan plot of
genotyped and imputed SNPs for association with
myopia (A,C) and hyperopia (B,D) in RS-I.
(TIF)
Figure S8 QQ and Genome-wide Manhattan plot of
genotyped and imputed SNPs for association with
myopia (A,C) and hyperopia (B,D) in RS-II.
(TIF)
Figure S9 QQ and Genome-wide Manhattan plot of
genotyped and imputed SNPs for association with
myopia (A,C) and hyperopia (B,D) in RS-III.
(TIF)
Figure S10 Flowchart showing the analysis workflows of
the entire study.
(TIF)
Table S1 Chromosomal regions selected to represent
loci reported to exhibit genome-wide significant or
suggestive association with myopia age at onset by
Kiefer et al. (2013).
(XLSX)
Table S2 Association results in our discovery meta-
analysis for the complete set of SNPs selected to
represent loci reported to exhibit genome-wide signifi-
cant or suggestive association with myopia age at onset
by Kiefer et al. (2013).
(XLSX)
Table S3 Baseline Characteristics of Samples Used in
the Replication of Our Discovery Meta-analysis Results.
(XLSX)
Table S4 Most significant associations with myopia in
the discovery GWAS meta-analysis.
(XLSX)
Table S5 Most significant associations with hyperopia
in the discovery GWAS meta-analysis.
(XLSX)
Table S6 Original Myopia Discovery Meta-analysis p-
value and Replication p-value from Meta-analysis of
Regional Results in 8 Replication Samples.
(XLSX)
Table S7 Original Hyperopia Discovery Meta-analysis
p-value and Replication p-value from Meta-analysis of
Regional Results in 8 Replication Samples.
(XLSX)
Table S8 Comparison of minor allele frequencies
(MAF) for each of the Kiefer et al. SNPs for the discovery
populations.
(XLSX)
Checklist S1 PRISMA Checklist.
(DOCX)
Materials S1 Replication Study Participants, Genotyp-
ing, Quality Control and Imputation.
(DOCX)
Materials S2 Association Analysis of Discovery Sam-
ples.
(DOCX)
Materials S3 Supplementary References.
(DOCX)
Acknowledgments
The Framingham Heart Study data were obtained from the NIH
repository dbGaP (accession numbers phs000007/HMB-IRB-MDS and
phs000007/HMB-IRB-NPU-MDS). This manuscript was not prepared in
collaboration with investigators of the Framingham Heart Study and does
not necessarily reflect the opinions or views of the Framingham Heart
Study, Boston University, or NHLBI. The following persons and
institutions participated in the DCCT/EDIC Study Research Group:
Study Chairmen - S. Genuth, D.M. Nathan, B. Zinman (vice-chair), O.
Crofford (past); Albert Einstein College of Medicine - J. Crandall, M. Reid,
J. Brown-Friday, S. Engel, J. Sheindlin, H. Martinez (past), H. Shamoon
(past), H. Engel (past), M. Phillips Case Western Reserve University - R.
Gubitosi-Klug, L. Mayer, S. Pendegast, H. Zegarra, D. Miller, L.
Singerman, S. Smith-Brewer, M. Novak, J. Quin (past), W. Dahms
(deceased), Saul Genuth (past), M. Palmert (past); Cornell University
Medical Center - D. Brillon, M.E. Lackaye, S. Kiss, R. Chan, V. Reppucci
(past), T. Lee (past), M. Heinemann (past) Henry Ford Health System - F.
Whitehouse, D. Kruger, J. K. Jones, M. McLellan (past), J.D. Carey, E.
Angus, A. Thomas, A. Galprin (past); International Diabetes Center - R.
Bergenstal, M. Johnson, M. Spencer (past), K. Morgan, D. Etzwiler
(deceased), D. Kendall (past) Joslin Diabetes Center - Lloyd Paul Aiello, E.
Golden, A. Jacobson (past), R. Beaser, O. Ganda, O. Hamdy, H. Wolpert,
G. Sharuk, P. Arrigg, D. Schlossman, J. Rosenzwieg (past), L. Rand (past);
Massachusetts General Hospital - D.M. Nathan, M. Larkin, M. Ong, J.
Godine, E. Cagliero, P. Lou, K. Folino, S. Fritz (past), S. Crowell (past), K.
Hansen (past), C. Gauthier-Kelly (past); Mayo Foundation - J. Service, G.
Ziegler Medical University of South Carolina - L. Luttrell, S. Caulder, M.
Lopes-Virella (past), J. Colwell (past), J. Soule (past), J. Fernandes, K.
Hermayer, S. Kwon, M. Brabham (past), A. Blevins, J. Parker, D. Lee
(past), N. Patel, C. Pittman, P. Lindsey (past), M. Bracey (past), K. Lee, M.
Nutaitis, A. Farr (past), S. Elsing (past), T. Thompson (past), J. Selby (past),
T. Lyons (past), S. Yacoub-Wasef (past), M. Szpiech (past), D. Wood (past),
R. Mayfield (past); Northwestern University - M. Molitch, B. Schaefer, L.
Jampol, A. Lyon, M. Gill, Z. Strugula, L. Kaminski, R. Mirza, E.
Simjanoski, D. Ryan; University of California, San Diego - O. Kolterman,
G. Lorenzi, M. Goldbaum University of Iowa - W. Sivitz, M. Bayless;
University of Maryland School of Medicine - D. Counts, S. Johnsonbaugh,
M. Hebdon (past), P. Salemi, R. Liss, T. Donner (past), J. Gordon (past), R.
Hemady (past), A. Kowarski (past), D. Ostrowski (past) S. Steidl (past), B.
Jones (past); University of Michigan - W.H. Herman, C.L. Martin, R. Pop-
Busui, A. Sarma, J. Albers, E. Feldman, K. Kim, S. Elner, G. Comer, T.
Gardner, R. Hackel, R. Prusak, L. Goings, A. Smith, J. Gothrup, P. Titus,
J. Lee, M. Brandle, L. Prosser, D.A. Greene (past), M.J. Stevens (past), A.
K. Vine (past); University of Minnesota - J. Bantle, N. Wimmergren, A.
Cochrane, T. Olsen (past), E. Steuer (past), P Rath (past), B. Rogness (past);
University of Missouri - D. Hainsworth, D. Goldstein, S. Hitt, J.
Giangiacomo; University of New Mexico - D.S. Schade, J.L. Canady,
J.E. Chapin, L.H. Ketai C; University of Pennsylvania – S. Braunstein,
P.A. Bourne, S. Schwartz (past), A. Brucker, B.J. Maschak-Carey (past), L.
Baker (deceased); University of Pittsburgh - T. Orchard, N. Silvers, C.
Ryan, T. Songer, B. Doft, S. Olson, R.L. Bergren, L. Lobes, P. Paczan
Rath, D. Becker, D. Rubinstein, P.W. Conrad, S. Yalamanchi, A. Drash
(past); University of South Florida - A. Morrison, M.L. Bernal, J. Vaccaro-
Kish (past), J. Malone, P.R. Pavan, N. Grove, M.N. Iyer, A.F. Burrows,
E.A. Tanaka (past), R. Gstalder (past); University of Tennessee - S.
Dagogo-Jack, C. Wigley, H. Ricks, A. Kitabchi, M. B. Murphy (past), S.
Moser (past), D. Meyer (past), A. Iannacone (past), E. Chaum, S. Yoser
(past), M. Bryer-Ash (past), S. Schussler (past), H. Lambeth (past); The
University of Texas Southwestern Medical Center at Dallas - P. Raskin, S.
Strowig; University of Toronto - B. Zinman, A. Barnie, R. Devenyi, M.
Mandelcorn, M. Brent, S. Rogers, A. Gordon; University of Washington -
J. Palmer, S. Catton, J. Brunzell, H. Wessells, I. H. de Boer, J. Hokanson, J.
Purnell, J. Ginsberg, J. Kinyoun, S. Deeb, M. Weiss, G. Meekins, J. Distad,
L. Van Ottingham (past); University of Western Ontario - J. Dupre, J.
Harth, D. Nicolle, M. Driscoll, J. Mahon, C. Canny; Vanderbilt University
- M. May, J. Lipps, A. Agarwal, T. Adkins, L. Survant, R. L. Pate, G. E.
Munn, R. Lorenz (past), S. Feman (past); Washington University, St. Louis
- N. White, L. Levandoski, I. Boniuk, G. Grand, M. Thomas, D. D.
Joseph, K. Blinder, G. Shah, Boniuk (past), Burgess (past), J. Santiago
(deceased); Yale University School of Medicine - W. Tamborlane, P.
Gatcomb, K. Stoessel, K. Taylor (past)J. Goldstein (past), S. Novella (past),
H. Mojibian (past), D. Cornfeld (past); Clinical Coordinating Center (Case
Genome-Wide Meta-Analysis of Myopia and Hyperopia
PLOS ONE | www.plosone.org 17 September 2014 | Volume 9 | Issue 9 | e107110
Western Reserve University) - R. Gubitosi-Klug, J. Quin, P. Gaston, M.
Palmert (past), R. Trail (past), W. Dahms (deceased); Data Coordinating
Center (The George Washington University, The Biostatistics Center) - J.
Lachin, P. Cleary, J. Backlund, W. Sun, B. Braffett, K. Klumpp, K. Chan
(past), L. Diminick, D. Rosenberg (past), B. Petty (past), A. Determan (past),
D. Kenny (past), B. Rutledge (past), Naji Younes (past), Williams (past), L.
Dews, M. Hawkins; National Institute of Diabetes and Digestive and
Kidney Disease Program Office - C. Cowie, J. Fradkin, C. Siebert (past), R.
Eastman (past); Central Fundus Photograph Reading Center (University of
Wisconsin) - R. Danis, S. Gangaputra, S. Neill, M. Davis (past), L.
Hubbard (past), H. Wabers, M. Burger, J. Dingledine, V. Gama, R.
Sussman; Central Biochemistry Laboratory (University of Minnesota) - M.
Steffes, J. Bucksa, M. Nowicki, B. Chavers; Central Carotid Ultrasound
Unit (New England Medical Center) - D. O9Leary, J. Polak, A.
Harrington, L. Funk (past); Central ECG Reading Unit (University of
Minnesota) – R. Crow (past), B. Gloeb (past), S. Thomas (past), C.
O9Donnell (past); Central ECG Reading Unit (Wake Forest University) –
E. Soliman, Z.M. Zhang, R. Prineas (past), C. Campbell; Central
Neuropsychological Coding Unit – C. Ryan, D. Sandstrom, T. Williams,
M. Geckle, E. Cupelli, F. Thoma, B. Burzuk, T. Woodfill; Central ANS
Reading Unit (Mayo Clinic) – P. Low, C. Sommer, K. Nickander;
Computed Tomography Reading Center (Harbor UCLA Research and
Education Institute) – M. Budoff, R. Detrano (past), N. Wong, M. Fox, L.
Kim (past), R. Oudiz; Johns Hopkins Medical Institutions – J. Lima, D.
Bluemke, E. Turkbey, R. J. van der Geest, C. Liu, A. Malayeri, A. Jain, C.
Miao (past), H. Chahal (past), R. Jarboe (past); External Evaluation
Committee– G. Weir (Chairman), M. Espeland, B. Klein, T Manolio, L.
Rand, D. Singer, M. Stern, A.E. Boulton, C. Clark (past), R. D9Agostino
(past); Molecular Risk Factors Program Project (Medical University of
South Carolina) - M. Lopes-Virella, W.T. Garvey (past), T.J. Lyons, A.
Jenkins, R. Klein, G. Virella, A. Jaffa, Rickey Carter, D. Lackland (past),
M. Brabham (past), D. McGee (past), D. Zheng (past), R. K. Mayfield
(past); Genetic Studies Group (Hospital for Sick Children) - A. Paterson, A.
Boright, S. Bull, L. Sun, S. Scherer (past), B. Zinman (past); SCOUT
(Veralight) – J. Maynard; Epigenetics (Beckman Research Institute of City
of Hope Medical Center) – R. Natarajan, F. Miao, L. Zhang, Z. Chen;
Editor, EDIC Publications - D.M. Nathan. For the current paper, the
Andrew D. Paterson serves as the DCCT/EDIC lead author and contact
person and is a named co-author of this paper.
We thank numerous clinicians, clinical staff, patients, and their families
for their participation in and dedication to the project; the Ogliastra
population and all the individuals who participated in this study. We are
very grateful to the municipal administrators for their collaboration to the
project and for economic and logistic support. We are extremely
appreciative of the support and wisdom provided by Dr. Hemin Chin of
the National Eye Institute. The Center for Inherited Disease Research,
fully funded through a federal contract (HHSN268200782096C) from
National Institutes of Health to The Johns Hopkins University, performed
genotyping of the AREDS and KORA cohorts. Clinical data and DNA
from the DCCT/EDIC study will be made available through the National
Institute of Diabetes and Digestive and Kidney Diseases repository at
https://www.niddkrepository.org/niddk/home.do. This manuscript was
not prepared under the auspices of and does not represent analyses or
conclusions of the NIDDK Central Repositories, or the NIH. Rotterdam
Study and ERF thank Ada Hooghart, Corina Brussee, Riet Bernaerts-
Biskop, Patricia van Hilten, Pascal Arp, Jeanette Vergeer, Marijn Verkerk
and Sander Bervoets.
Author Contributions
Conceived and designed the experiments: DS JEBW TM RW CLS KO
VV MS LIR MFC EC BEKK RK TYW CMvD PM SMS JJW HC IR
BAO AGU AH FR NA LCK JRV AD TB GB CG HW JFW BF JSR CJH
CH AFW ADP PNB CCWK JIR MP DCCT/EDIC. Analyzed the data:
RW CLS KO FM LP XL VJMV VVMS SMH PGH CV PMC CJH PNB
JEBW. Wrote the paper: CLS RW KO JEBW DS. Enrolled participants
and collected study data: KO LJR MFC EC BEKK RK TYW CMvD RM
SMS MF JJW OP BAO AGU AH FR NA LCK JRV AD TB GB CG HW
JFW BF JSR CJH CH ADP CCWK JIR TM DCCT/EDIC.
References
1. Kempen JH, Mitchell P, Lee KE, Tielsch JM, Broman AT, et al. (2004) The
prevalence of refractive errors among adults in the United States, Western
Europe, and Australia. Arch Ophthalmol 122: 495–505.
2. Vitale S, Sperduto RD, Ferris FL 3rd (2009) Increased prevalence of myopia in
the United States between 1971–1972 and 1999–2004. Arch Ophthalmol 127:
1632–1639.
3. He M, Zeng J, Liu Y, Xu J, Pokharel GP, et al. (2004) Refractive error and
visual impairment in urban children in southern china. Invest Ophthalmol Vis
Sci 45: 793–799.
4. Lin LL, Shih YF, Hsiao CK, Chen CJ (2004) Prevalence of myopia in
Taiwanese schoolchildren: 1983 to 2000. Ann Acad Med Singapore 33: 27–33.
5. Edwards MH, Lam CS (2004) The epidemiology of myopia in Hong Kong. Ann
Acad Med Singapore 33: 34–38.
6. Lee JH, Jee D, Kwon JW, Lee WK (2013) Prevalence and risk factors for myopia
in a rural korean population. Invest Ophthalmol Vis Sci 54: 5466–5471.
7. Wojciechowski R (2011) Nature and nurture: the complex genetics of myopia
and refractive error. Clin Genet 79: 301–320.
8. Sanfilippo PG, Hewitt AW, Hammond CJ, Mackey DA (2010) The heritability
of ocular traits. Surv Ophthalmol 55: 561–583.
9. Teikari J, Koskenvuo M, Kaprio J, O9Donnell J (1990) Study of gene-
environment effects on development of hyperopia: a study of 191 adult twin
pairs from the Finnish Twin Cohort Study. Acta Genet Med Gemellol (Roma)
39: 133–136.
10. Teikari JM, Kaprio J, Koskenvuo MK, Vannas A (1988) Heritability estimate
for refractive errors–a population-based sample of adult twins. Genet Epidemiol
5: 171–181.
11. Wojciechowski R, Congdon N, Bowie H, Munoz B, Gilbert D, et al. (2005)
Heritability of refractive error and familial aggregation of myopia in an elderly
American population. Invest Ophthalmol Vis Sci 46: 1588–1592.
12. Peet JA, Cotch MF, Wojciechowski R, Bailey-Wilson JE, Stambolian D (2007)
Heritability and familial aggregation of refractive error in the Old Order Amish.
Invest Ophthalmol Vis Sci 48: 4002–4006.
13. Ip JM, Rose KA, Morgan IG, Burlutsky G, Mitchell P (2008) Myopia and the
urban environment: findings in a sample of 12-year-old Australian school
children. Invest Ophthalmol Vis Sci 49: 3858–3863.
14. Ip JM, Saw SM, Rose KA, Morgan IG, Kifley A, et al. (2008) Role of near work
in myopia: findings in a sample of Australian school children. Invest Ophthalmol
Vis Sci 49: 2903–2910.
15. Dirani M, Tong L, Gazzard G, Zhang X, Chia A, et al. (2009) Outdoor activity
and myopia in Singapore teenage children. British Journal of Ophthalmology
93: 997–1000.
16. Rose KA, Morgan IG, Ip J, Kifley A, Huynh S, et al. (2008) Outdoor activity
reduces the prevalence of myopia in children. Ophthalmology 115: 1279–1285.
17. Stambolian D (2013) Genetic susceptibility and mechanisms for refractive error.
Clin Genet 84: 102–108.
18. Kiefer AK, Tung JY, Do CB, Hinds DA, Mountain JL, et al. (2013) Genome-
wide analysis points to roles for extracellular matrix remodeling, the visual cycle,
and neuronal development in myopia. PLoS Genet 9: e1003299.
19. Verhoeven VJ, Hysi PG, Wojciechowski R, Fan Q, Guggenheim JA, et al. (2013)
Genome-wide meta-analyses of multiancestry cohorts identify multiple new
susceptibility loci for refractive error and myopia. Nat Genet 45: 314–318.
20. Wojciechowski R, Hysi PG (2013) Focusing in on the complex genetics of
myopia. PLoS Genet 9: e1003442.
21. Verhoeven VJ, Hysi PG, Saw SM, Vitart V, Mirshahi A, et al. (2012) Large scale
international replication and meta-analysis study confirms association of the
15q14 locus with myopia. The CREAM consortium. Human Genetics.
22. Sanna S, Jackson AU, Nagaraja R, Willer CJ, Chen WM, et al. (2008) Common
variants in the GDF5-UQCC region are associated with variation in human
height. Nat Genet 40: 198–203.
23. Devlin B, Roeder K (1999) Genomic control for association studies. Biometrics
55: 997–1004.
24. Stambolian D, Wojciechowski R, Oexle K, Pirastu M, Li X, et al. (2013) Meta-
analysis of genome-wide association studies in five cohorts reveals common
variants in RBFOX1, a regulator of tissue-specific splicing, associated with
refractive error. Hum Mol Genet 22: 2754–2764.
25. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly
identified loci that influence lipid concentrations and risk of coronary artery
disease. Nat Genet 40: 161–169.
26. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. American Journal of Human Genetics 81: 559–575.
27. Ioannidis JP (2007) Non-replication and inconsistency in the genome-wide
association setting. Hum Hered 64: 203–213.
28. Kraft P, Zeggini E, Ioannidis JP (2009) Replication in genome-wide association
studies. Stat Sci 24: 561–573.
29. Ioannidis JP, Thomas G, Daly MJ (2009) Validating, augmenting and refining
genome-wide association signals. Nat Rev Genet 10: 318–329.
Genome-Wide Meta-Analysis of Myopia and Hyperopia
PLOS ONE | www.plosone.org 18 September 2014 | Volume 9 | Issue 9 | e107110
30. Roeder K, Bacanu SA, Wasserman L, Devlin B (2006) Using linkage genome
scans to improve power of association in genome scans. Am J Hum Genet 78:
243–252.
31. Wang K, Li M, Bucan M (2007) Pathway-based approaches for analysis of
genomewide association studies. Am J Hum Genet 81: 1278–1283.
32. Li M, Wang K, Grant SF, Hakonarson H, Li C (2009) ATOM: a powerful gene-
based association test by combining optimally weighted markers. Bioinformatics
25: 497–503.
33. Gauderman WJ, Murcray C, Gilliland F, Conti DV (2007) Testing association
between disease and multiple SNPs in a candidate gene. Genet Epidemiol 31:
383–395.
34. Wang T, Elston RC (2007) Improved power by use of a weighted score test for
linkage disequilibrium mapping. Am J Hum Genet 80: 353–360.
35. Wu MC, Kraft P, Epstein MP, Taylor DM, Chanock SJ, et al. (2010) Powerful
SNP-set analysis for case-control genome-wide association studies. Am J Hum
Genet 86: 929–942.
36. Kwee LC, Liu D, Lin X, Ghosh D, Epstein MP (2008) A powerful and flexible
multilocus association test for quantitative traits. Am J Hum Genet 82: 386–397.
37. Wang K, Abbott D (2008) A principal components regression approach to
multilocus genetic association studies. Genet Epidemiol 32: 108–118.
38. Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, et al. (2010) A versatile
gene-based test for genome-wide association studies. Am J Hum Genet 87: 139–
145.
39. Christoforou A, Dondrup M, Mattingsdal M, Mattheisen M, Giddaluru S, et al.
(2012) Linkage-disequilibrium-based binning affects the interpretation of
GWASs. Am J Hum Genet 90: 727–733.
40. Ramos E, Chen G, Shriner D, Doumatey A, Gerry NP, et al. (2011) Replication
of genome-wide association studies (GWAS) loci for fasting plasma glucose in
African-Americans. Diabetologia 54: 783–788.
41. Dudbridge F, Gusnanto A (2008) Estimation of significance thresholds for
genomewide association scans. Genetic Epidemiology 32: 227–234.
42. Duggal P, Gillanders EM, Holmes TN, Bailey-Wilson JE (2008) Establishing an
adjusted p-value threshold to control the family-wide type 1 error in genome
wide association studies. BMC Genomics 9: 516.
43. Nyholt DR (2004) A simple correction for multiple testing for single-nucleotide
polymorphisms in linkage disequilibrium with each other. American Journal of
Human Genetics 74: 765–769.
44. Cheverud JM (2001) A simple correction for multiple comparisons in interval
mapping genome scans. Heredity 87: 52–58.
45. Li J, Ji L (2005) Adjusting multiple testing in multilocus analyses using the
eigenvalues of a correlation matrix. Heredity 95: 221–227.
46. Bretherton CS, Widmann M, Dymnikov VP, Wallace JM, Blade I (1999) The
effective number of spatial degrees of freedom of a time-varying field. Journal of
Climate 12: 1990–2009.
47. Willer CJ, Li Y, Abecasis GR (2010) METAL: fast and efficient meta-analysis of
genomewide association scans. Bioinformatics 26: 2190–2191.
48. Solouki AM, Verhoeven VJ, van Duijn CM, Verkerk AJ, Ikram MK, et al.
(2010) A genome-wide association study identifies a susceptibility locus for
refractive errors and myopia at 15q14. Nature Genetics 42: 897–901.
49. Verhoeven VJ, Hysi PG, Wojciechowski R, Fan Q, Guggenheim JA, et al. (2013)
Genome-wide meta-analyses of multiancestry cohorts identify multiple new
susceptibility loci for refractive error and myopia. Nat Genet 45: 314–318.
50. Blanco-Aguirre ME, Kofman-Alfaro SH, Rivera-Vega MR, Medina C, Valdes-
Flores M, et al. (2001) Unusual clinical presentation in two cases of multiple
sulfatase deficiency. Pediatr Dermatol 18: 388–392.
51. Lerche C, Scherer CR, Seebohm G, Derst C, Wei AD, et al. (2000) Molecular
cloning and functional expression of KCNQ5, a potassium channel subunit that
may contribute to neuronal M-current diversity. The Journal of biological
chemistry 275: 22395–22400.
52. Pattnaik BR, Hughes BA (2012) Effects of KCNQ channel modulators on the
M-type potassium current in primate retinal pigment epithelium. American
journal of physiology Cell physiology 302: C821–833.
53. Zhang X, Yang D, Hughes BA (2011) KCNQ5/K(v)7.5 potassium channel
expression and subcellular localization in primate retinal pigment epithelium
and neural retina. American journal of physiology Cell physiology 301: C1017–
1026.
54. Itzkovitz B, Jiralerspong S, Nimmo G, Loscalzo M, Horovitz DD, et al. (2012)
Functional characterization of novel mutations in GNPAT and AGPS, causing
rhizomelic chondrodysplasia punctata (RCDP) types 2 and 3. Hum Mutat 33:
189–197.
55. Wang Q, Zhao G, Xing S, Zhang L, Yang X (2011) Role of bone
morphogenetic proteins in form-deprivation myopia sclera. Mol Vis 17: 647–
657.
56. Zhang Y, Liu Y, Wildsoet CF (2012) Bidirectional, optical sign-dependent
regulation of BMP2 gene expression in chick retinal pigment epithelium. Invest
Ophthalmol Vis Sci 53: 6072–6080.
57. Reddi AH, Reddi A (2009) Bone morphogenetic proteins (BMPs): from
morphogens to metabologens. Cytokine Growth Factor Rev 20: 341–342.
Genome-Wide Meta-Analysis of Myopia and Hyperopia
PLOS ONE | www.plosone.org 19 September 2014 | Volume 9 | Issue 9 | e107110
